 |
|
|
|
|
- Kerstin M. Bode-Greuel, Joachim M. Greuel and Klaus J. Nickisch: How can pharmaceutical and biotech companies maintain a high profitability? Journal of Commercial Biotechnology (2008) in print
- Kerstin M. Bode-Greuel and Klaus J. Nickisch: Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development - Commonalities and differences in portfolio management practice. Journal of Commercial Biotechnology, October 2008
- Joachim M. Greuel: Pharma and Biotech: Is it possible to continue growing? Pharma Focus Asia (2008), Issue 6,6-9
- Kerstin M. Bode-Greuel and Joachim M. Greuel: Ermittlung des Wertes von Entwicklungskandidaten und Technologieplattformen für Arzneistoffe. Bewertung von Biotechnologie-Unternehmen, Chaper 15, published by Prof. Dr. Dr. h.c. J. Drukarcyzk, Wirtschaft-Wissenschaftslehre, University of Regensburg; Prof. Dr. Dr. Dietmar Ernst, Fachgebiet Bankwirtschaft, Fachhochschule Nürtingen; now adopted as university textbook, 3rd edition planned
- Kerstin M. Bode-Greuel and Joachim M. Greuel: Determining the value of drug development candidates and technology platforms. Journal of Commercial Biotechnology (2005) Vol. 11 No. 2, ISSN 1462-8732, 155-170
-
Joachim M. Greuel: Assessing the economics of biogenerics. Journal of Generic Medicines (2005), Volume 2, Issue 2, January 2005, ISSN 1741-1343, 153-160
-
Joachim M. Greuel: The R&D value conundrum. Current Drug Discovery, July 2002, 37-42
-
Christoph H. Loch and Kerstin Bode-Greuel: Evaluating growth options as sources of value for pharmaceutical research projects. R&D Management (2001) Vol. 31 No. 2, ISSN 0033-6807, 231-248
-
Kerstin Bode-Greuel: Real Options Evaluation in Pharmaceutical R&D: a new approach to financial project evaluation. SCRIP Reports, Strategic Management Series, (Feb. 2000), Ref. BS1038, pages: 142
-
Kerstin M. Bode-Greuel: Making wise decisions in pharmaceutical investment. Scrip Magazine (June 1998), 27-28, PJB Publications
-
Kerstin M. Bode-Greuel: Financial Project Evaluation and Risk Analysis in Pharmaceutial Development. SCRIP Reports, Strategic Management Series, (Nov. 1997), Ref: BS890, pages: 164
|
|
